Heron Therapeutics: Generic Competition And HTX-011 Approval May Put Pressure On Share Price [Seeking Alpha]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Seeking Alpha
Summary Heron Therapeutics' 2 commercialised drugs for the treatment of acute and delayed nausea and vomiting associated with types of chemotherapy are under pressure from generic competition. Net sales of Cinvanti for the first nine months of 2019 grew by 197% to $97.6m year-on-year but sales of Sustol decreased by 19% to $13.8m over the same period. Q4 preliminary data suggests Cinvanti ($34.8m) sales dropped slightly quarter-on-quarter whilst Sustol's collapsed from $6.3m (in Q3) to $0.4m as a result of ALOXI/Palonosetron Arbitrage. Heron has re-submitted its NDA for extended release local anaesthetic HTX-011 after receiving a CRL related to CMC concerns in April '19. Approval is likely to be granted in June. If Cinvanti sales are hit as badly by generics as Sustol's Heron will need HTX-011 to deliver triple-digit million sales quickly. Until there is more clarity I am bearish. Investment Thesis Heron Therapeutics ( HRTX The three main issues the company faces are the FDA's rejecti
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain [Seeking Alpha]Seeking Alpha
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York CityPR Newswire
- Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.MarketBeat
- ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
HRTX
Earnings
- 3/12/24 - Beat
HRTX
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form PRE
- 4/19/24 - Form 4
- HRTX's page on the SEC website